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cardiac (often sudden) death. The use of highly puriﬁed omega-
3 polyunsaturated fatty acids (n-3 PUFAs) in addition to 
standard secondary prevention after MI results in a signiﬁcant
reduction in risk of sudden death. OBJECTIVE: To assess the
cost-effectiveness of adding n-3 PUFAs to the current secondary
prevention treatment after acute MI in ﬁve countries (Australia,
Belgium, Canada, Germany, Poland). METHODS: Based on the
clinical outcomes of GISSI-Prevenzione (MI, stroke, revasculari-
sation rate and mortality), a decision model was built in 
DataProTM. The implications of adding n-3 PUFAs to standard
treatment in patients with a recent history of MI were analysed
from the health care payer’s perspective. The time horizon was
3.5 years (identical to GISSI-Prevenzione). Event costs were
based on literature data. Life expectancy data for survivors of
cardiac disease were obtained from the Saskatchewan database
and country-adjusted. Results are expressed as extra cost (€) per
life year gained (LYG). Country-speciﬁc discounting was applied
to costs and effects. RESULTS: Treatment with n-3 PUFAs
yielded between 0.265 (Poland) and 0.289 (Canada) LYG, at an
additional cost of 823€ (Canada) to 1479€ (Belgium). The incre-
mental cost-effectiveness ratio (ICER) varied between 2850€
(Canada) and 5154€ (Belgium) per LYG. Sensitivity analyses on
effectiveness, cost of complications and discounting proved the
robustness of the results. A second order Monte Carlo simula-
tion based on the 95% CIs obtained from GISSI showed that 
n-3 PUFAs are cost-effective in more than 99% of patients
(threshold 20,000€/LYG). Including costs incurred during LYG
considerably increased total costs, but had no impact on the
ICER-based treatment recommendation. CONCLUSIONS:
Adding highly puriﬁed n-3 PUFAs to standard treatment in the
secondary prevention after MI appears to be cost-effective in the
ﬁve countries studied.
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OBJECTIVES: To investigate the cost trend of anticoagulant
drug usage in hospital inpatients, examine the association among
patients’ DRG groups, average length of therapy, and their drug
costs. METHODS: A sample of four-million hospital discharges
from 251 hospitals treated with an anticoagulant (Angiomax,
Argatroban, Arixtra, Coumadin, Dicumarol, Fragmin, Heparin
sodium, Innohep, Lovenox, Miradon, Orgaran ,Reﬂudan and
Thrombate III) between 1998 and 2004 was retrieved. The
sample was also broken out by the DRG group as unstable
angina non-ST-segment elevation myocardial infarction
(UANSTEMI), ST-segment elevation myocardial infarction
(STEMI), deep vein thrombosis (DVT), abdominal disease, and
other group. The average anticoagulant cost was estimated as a
linear function of lab, image, supply,length of therapy,length of
stay,time etc. Analysis of Variance model was created to examine
if the drug volume is determined by drug cost, DRG group, and
average length of therapy. RESULT: Although each single drug
cost per discharge remained unchanged or even decreases over
time, the average anticoagulant drug cost per discharge increases
with time (p-value <+) and with average length of therapy (p-
value <+). This was because newer, or relatively more expensive
drugs like Argatroban, Orgaran, Arixtra and Angiomax etc.
were introduced during the time frame. Drug volume is function
of average length of therapy (p-value <+) and average drug cost
(p-value <+); however, DRG group was not a signiﬁcant factor.
The results held if examining each drug like Lovenox or Heparin
sodium separately. As newer drugs were introduced, the average
length of hospital stay (p-value <+) decreased. CONCLUSION:
The use of large market share drugs (Heparin, Lovenox, Fragmin
etc) remained stable for hospital inpatient over time. However,
there was tendency to use newer, more expensive drugs to
improve clinical outcomes regardless of increasing anticoagulant
drug costs.
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OBJECTIVE: One of the most serious and frequent conse-
quences of acute myocardial infarction is heart failure, which has
moved into the focus of public health care in the last few years.
The presented modeling determines the epidemiological and
health-economic disease burden of post-acute myocardial infarc-
tion heart failure in Germany. METHODS: Basis for the concept
was a literature review of relevant publications since 1990. The
incidence of post-acute myocardial infarction heart failure was
estimated for two scenarios and, with the help of a Markov
model, the course of the disease and the associated use of
resources over a period of nine years was calculated. Subse-
quently, the annual cost of all prevalent cases was determined.
RESULTS: The calculation of the incidence in Germany varies
between 50,000 (best case scenario) and 90,000 (worst case 
scenario) per year. These patients cause total costs of 1.4–2.5 
billion euro during the selected observation period (the portion
of direct costs is approx. 55 %). The prevalence per year is 
estimated to be 250,000 to 450,000. Per year these patients 
cause a ﬁnancial burden of approximately 0.9–1.6 billion Euros.
The majority is due to hospital treatment (0.3–0.5 billion Euros)
and the loss of productivity due to premature mortality (0.2–
0.4 billion Euros). Apart from the rateable monetary strain, it
has to be assumed that after the manifestation of heart failure
the quality of life for these patients is reduced by about 50%
compared to that of the normal population at a comparable age.
CONCLUSION: In light of the heavy ﬁnancial burden—in par-
ticular due to hospital treatment and loss of productivity—
following the manifestation of heart failure, an early and 
effective therapy of the initial myocardial infarction is essential.
If heart insufﬁciency nevertheless develops following myocardial
infarction, optimum secondary preventive strategies are 
necessary.
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People with the metabolic syndrome are at increased risk for 
cardiovascular disease (CVD). Screening of metabolic syndrome
allows early recognition of individuals at risk for developing
CVD. OBJECTIVE: To examine the frequency and risk factors
of metabolic syndrome among the Korean Americans living in
New York City. METHODS: This is a cross-sectional health
examination survey. Using a standardized questionnaire, blood
pressure (BP), body mass index (BMI), waist to hip ratio (WHR)
were recorded; serum total cholesterol (TC), high-density
lipoprotein (HDL), fasting triglycerides (FTG), and fasting
